GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches boosting long-term growth.

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

This has lagged the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08% in that time. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Eli Lilly said Monday it would acquire an experimental cancer ... the genomics company Illumina and the academic medical center Mayo Clinic. Partnerships are a key pillar of Nvidia's health-care ...

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

Eli Lilly is seeking to end a lawsuit filed by ... And in the nearly two years that tirzepatide was in shortage, telehealth companies, medical spas and other clients of compounding pharmacies ...